ATE412402T1 - Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen - Google Patents

Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen

Info

Publication number
ATE412402T1
ATE412402T1 AT06759259T AT06759259T ATE412402T1 AT E412402 T1 ATE412402 T1 AT E412402T1 AT 06759259 T AT06759259 T AT 06759259T AT 06759259 T AT06759259 T AT 06759259T AT E412402 T1 ATE412402 T1 AT E412402T1
Authority
AT
Austria
Prior art keywords
ophthalmic
poloxamine
adjusting agent
medication
preparing
Prior art date
Application number
AT06759259T
Other languages
English (en)
Inventor
Geoffrey Owen
Amy Brooks
Gustav Graff
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ATE412402T1 publication Critical patent/ATE412402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT06759259T 2005-05-10 2006-05-08 Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen ATE412402T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67951005P 2005-05-10 2005-05-10

Publications (1)

Publication Number Publication Date
ATE412402T1 true ATE412402T1 (de) 2008-11-15

Family

ID=37087751

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06759259T ATE412402T1 (de) 2005-05-10 2006-05-08 Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen

Country Status (19)

Country Link
US (1) US20060257486A1 (de)
EP (1) EP1906916B1 (de)
JP (1) JP4968955B2 (de)
KR (1) KR20080011311A (de)
CN (1) CN101175476B (de)
AT (1) ATE412402T1 (de)
AU (1) AU2006244245B2 (de)
BR (1) BRPI0608774A2 (de)
CA (1) CA2607014A1 (de)
CY (1) CY1108676T1 (de)
DE (1) DE602006003438D1 (de)
DK (1) DK1906916T3 (de)
ES (1) ES2313670T3 (de)
MX (1) MX2007014084A (de)
PL (1) PL1906916T3 (de)
PT (1) PT1906916E (de)
SI (1) SI1906916T1 (de)
WO (1) WO2006121964A2 (de)
ZA (1) ZA200709296B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
TW200812575A (en) * 2006-04-28 2008-03-16 Alcon Inc Formulations containing amide derivatives of carboxylic acid NSAIDs for topical administration to the eye
TW201023912A (en) * 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
MX2011008680A (es) * 2009-03-03 2011-09-08 Alcon Res Ltd Composicion farmaceutica para el suministro de compuestos inhibidores de la tirosina cinasa receptora (rtki) para los ojos.
US8912236B2 (en) * 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
HUE038821T2 (hu) * 2009-12-03 2018-11-28 Novartis Ag Karboxivinil polimert tartalmazó nanorészecske szuszpenziók
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
CN103079595B (zh) * 2010-08-27 2015-11-25 若素制药株式会社 滴眼用水性组合物
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN111285845B (zh) * 2020-02-11 2021-01-01 深圳厚存纳米药业有限公司 末端官能团化的泊洛沙胺衍生物
US12049606B2 (en) * 2021-01-12 2024-07-30 Johnson & Johnson Vision Care, Inc. Compositions for ophthalmologic devices
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
CA3206106A1 (en) * 2021-02-10 2022-08-18 Bhaskar Chaudhuri Methods for ophthalmic delivery of roflumilast
CA3231766A1 (en) 2021-09-22 2023-03-30 Elizabeth W. JEFFORDS Methods of treating ocular inflammatory diseases
AU2023342481A1 (en) * 2022-09-15 2025-04-10 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
DE3882042T2 (de) * 1987-12-25 1993-09-30 Santen Pharma Co Ltd Antiallergische augentropfen.
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
ES2227331T3 (es) * 1997-07-29 2005-04-01 Alcon Laboratories, Inc. Soluciones de acondicionamiento para el cuidado de las lentes de contacto duras.
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (de) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmische Zusammensetzung
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US20020115578A1 (en) * 2000-12-14 2002-08-22 Groemminger Suzanne F. Composition for cleaning and wetting contact lenses
WO2002078681A2 (en) * 2001-04-02 2002-10-10 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders using an amide derivative of flubiprofen or ketorolac
JP2003137775A (ja) * 2001-10-31 2003-05-14 Menicon Co Ltd 眼科用組成物
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
EP1487430A4 (de) * 2002-02-28 2007-08-22 Icagen Inc Verfahren zur behandlung von erkrankungen im zusammenhang mit dem augeninnendruck
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
EP1611883A1 (de) * 2003-03-26 2006-01-04 Menicon Co., Ltd. Zusammensetzung zur verwendung für die augen
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
US20060257487A1 (en) * 2005-05-10 2006-11-16 Alcon, Inc. Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders

Also Published As

Publication number Publication date
CA2607014A1 (en) 2006-11-16
CY1108676T1 (el) 2014-04-09
ZA200709296B (en) 2009-01-28
US20060257486A1 (en) 2006-11-16
PL1906916T3 (pl) 2009-02-27
DK1906916T3 (da) 2009-01-19
WO2006121964A2 (en) 2006-11-16
JP4968955B2 (ja) 2012-07-04
WO2006121964A3 (en) 2007-03-22
PT1906916E (pt) 2008-12-10
DE602006003438D1 (de) 2008-12-11
ES2313670T3 (es) 2009-03-01
CN101175476B (zh) 2011-11-16
MX2007014084A (es) 2008-02-07
EP1906916A2 (de) 2008-04-09
EP1906916B1 (de) 2008-10-29
AU2006244245A1 (en) 2006-11-16
AU2006244245B2 (en) 2010-11-18
JP2008540533A (ja) 2008-11-20
BRPI0608774A2 (pt) 2010-01-26
SI1906916T1 (sl) 2009-02-28
KR20080011311A (ko) 2008-02-01
CN101175476A (zh) 2008-05-07

Similar Documents

Publication Publication Date Title
ATE428401T1 (de) Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
ATE412402T1 (de) Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol- tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
NO20075136L (no) Nye liposompreparater
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
PH12015501207A1 (en) Amine derivative compounds for treating ophthalmic diseases and disorders
GEP20094781B (en) Sulfonamide derivatives for the treatment of diseases
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
ATE535257T1 (de) Ophthalmologische formulierung mit methylsulfonylmethan und ciprofloxacin
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2010028088A3 (en) Sulfur-linked compounds for treating opthalmic diseases and disorders
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo
WO2006081363A3 (en) Oral formulations for delivery of catecholic butanes including ndga compounds
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
NO20064521L (no) Framgangsmate og blanding for behandling av rhinitt
ATE384529T1 (de) Synergistische kombination enthaltend roflumilast und einen anticholinergischen wirkstoff ausgewählt aus tiotropiumsalzen für die behandlung von atemwegserkrankungen
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
ATE425741T1 (de) Arzneizubereitung und deren anwendung zur behandlung von erkrankungen des inneren ohres
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico
UA37620A (uk) Очна мазь

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1906916

Country of ref document: EP